 Roche Group

Overview of R&D Activities

CHUGAI PHARMACEUTICAL CO., LTD.
Senior Vice President
Head of Strategic Marketing Unit and
General Manager of Strategic Planning Dept.
Tatsuro Kosaka

January 30/ 31, 2008

Forward Looking Statements

This presentation may include forward looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

R&D Topics (October 2007 ~ January 2008)

2007

- Nov MRA (Actemra) : Filed application for rheumatoid arthritis in United States and Europe (Roche)
- Dec R340 (Xeloda) : Approved and launched for additional indication of monotherapy treatment in adjuvant colon cancer and global dosage and administration for breast cancer
- Dec R1415(Tarceva) : Approved and launched for non-small cell lung cancer
- Dec R1594 : Joined multinational phase III study with Roche/Genentech for rheumatoid arthritis
- Dec EPOCH(Epogin) : Withdrew the application for additional dosage and administration for renal anemia in hemodialysis patients

Projects under Development (as of Jan 2008)


	Phase I	Phase II	Phase III	Filed
Oncology	<i>R1273 (NSCLC)</i> <i>TP300(CRC)</i>	<i>Actemra (multiple myeloma)</i> <i>Xeloda (CRC/ combo)</i> <i>Avastin (NSCLC)</i> <i>Avastin (BC)</i> <i>Tarceva (PC)</i> <i>R744 (Mircera CIA)</i>	<i>Epogin (CIA)</i> <i>Avastin (Adj. CC)#</i> <i>Avastin (GC)#</i> <i>Herceptin (GC)#</i> <i>Xeloda (GC)</i>	<i>Herceptin (Adj. BC)#</i>
Bone & Joint		<i>R484</i> <i>(Bonviva oral osteoporosis)</i>	<i>R484 (Bonviva iv osteoporosis)</i> <i>ED-71(osteoporosis)</i> <i>Actemra (sJIA)</i> <i>R1594 (RA)</i>	<i>Actemra (RA)</i> <i>Actemra (sJIA)</i> <i>Actemra (RA)</i>
Renal			<i>R744</i> <i>(Mircera renal anemia)</i>	
Transplant, Immunology Infection	<i>Actemra (SLE)</i> <i>Actemra</i> <i>(castleman's disease)</i> <i>NA808 (chronic hepatitis C)</i>	<i>Actemra</i> <i>(crohn's disease)</i>	<i>Pegasys / Copegus (liver cirrhosis)</i> <i>Pegasys (chronic hepatitis B)</i>	
Others	<i>*GM-611</i> <i>(diabetic gastroparesis)</i> <i>R1678 (schizophrenia)</i> <i>R1583 (type II diabetes)</i> <i>CSG452 (type II diabetes)</i>	<i>*GM-611(IBS)</i> <i>*GM-611(diabetic gastroparesis)</i>		<i>AVS</i> <i>(subarachnoidal hemorrhage)</i> <i>Epogin</i> <i>(autologous transfusion)</i>

*GM-611 is being considered for out-licensing

(Italics: Roche projects, Underlined: overseas' clinical development, #: participation in multi-national studies)

Projected Submissions

Filings planned each year



Contacts:

Corporate Communications Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607

e-mail: pr@chugai-pharm.co.jp

Masayuki Yamada, Seiji Shimada, Hiroshi Araki

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607

e-mail: ir@chugai-pharm.co.jp

Mac Uchida, Kae Maeda, Tomoko Shimizu, Yusuke Tokita